The SMART B Exercise Study :''The SMART Study''

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-14

Study Completion Date

2022-10-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Despite the established health benefits conveyed by physical activity for people with type 1 diabetes (T1D), participation rates remain low, with fear of hypoglycaemia, lack of freedom to engage in unplanned activities, and uncertainty in making appropriate adjustments to insulin and nutritional therapy reported as the leading barriers to regular exercise engagement. Indeed, the synergistic glucose lowering effects of peripheral hyperinsulinaemia and exercising muscle tissue accentuate the risk of exercise-related hypoglycaemia for individuals with T1D, particularly if performed post-prandially. Hence, the introduction of commercially available artificial pancreas systems, also known as ''advanced hybrid-closed-loop'' (AHCL) systems, that regulate insulin rates with minimal user interaction constitute compelling therapeutic aids with clinically relevant potential. Nevertheless, we know little about their safe and efficacious integration around dynamic physical exercise. Nor do we know how alterations in carbohydrate fueling strategies around exercise effect subsequent glucose trends.

This study aims to 1) compare the efficacy of an AHCL system versus usual care insulin pump therapy, with carbohydrates taken before or during exercise, in optimising TIR around dynamic physical exercise and 2) explore the influence of carbohydrate intake before versus during exercise on the metabolomic, hormonal and physiological responses to exercise.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The SMART A Exercise Study :''The SMART Study''

NCT05134025

Type 1 Diabetes

COMPLETED NA

Real-life Follow-up of the Physical Activity in Type 1 Diabetes Participants Equipped With an Insulin Pump With Hybrid Closed Loop

NCT07015970

Diabetes Mellitus Type 1 Glucose Metabolism Disorder Glycemic Control for Diabetes Mellitus +4 more

COMPLETED

Accelerometer Use in the Prevention of Exercise-Associated Hypoglycemia in Type 1 Diabetes: Outpatient Exercise Protocol

NCT02047643

Type 1 Diabetes

COMPLETED NA

Validation of Algorithms for Basal Insulin Rate Reductions in Type 1 Diabetic Patients Practising Physical Activity

NCT01277965

Type 1 Diabetes With a Subcutaneous Insulin Pump Adjustment of the Recommended Basal Insulin Flow Rate in the Event of Physical Activity Adjustment of the Recommended Prandial Insulin in the Event of Physical Activity

COMPLETED NA

Suspending Basal Insulin Levels for Exercise in Adults With Type 1 Diabetes

NCT03034798

Type1 Diabetes Mellitus Physical Activity Hypoglycemia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Following successful completion of a screening visit, participants will attend the laboratory to complete 3 experimental visits during which they will undertake a 45-minute bout of moderate intensity continuous exercise on a bicycle ergometer at \~60% of the individualised VȮ2max. Prior to commencing exercise, participants will consume a standardised low-glycaemic index, carbohydrate-based meal (equating to 0.75g.CHO.kg.bm-1) with, or without, a 25% reduction in their meal-time insulin dose as well as with carbohydrates before or during exercise (according to the randomisation). Venous blood glucose sampling will be taken in 15-minute intervals leading into and after exercise with 5-minute intervals performed during exercise. Samples will be used to retrospectively cross-compare the metabolic, hormonal, and physiological responses between visits. Visits 1 \& 2 will be separated by ≥14 days to ensure adequate familiarisation with the AHCL system whilst visits 2 \& 3 will be separated by ≥3days. Each participant will undertake 1 screening and 3 experimental visits equating to a total of 80 study visits.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypoglycemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Three period randomised cross-over clinical trial

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SMART B1 - Usual care insulin pump

Usual care pump therapy arm with carbohydrate consumption before exercise

Group Type EXPERIMENTAL

Insulin pump

Intervention Type DEVICE

Alterations in insulin pump therapy or carbohydrate consumption

SMART B2 - Advanced hybrid closed loop insulin pump with carbohydrates before exercise

Advanced hybrid closed loop therapy arm with carbohydrate consumption before exercise

Group Type EXPERIMENTAL

Insulin pump

Intervention Type DEVICE

Alterations in insulin pump therapy or carbohydrate consumption

SMART B3 - Advanced hybrid closed loop insulin pump with carbohydrates during exercise

Advanced hybrid closed loop therapy arm with carbohydrate consumption during exercise

Group Type EXPERIMENTAL

Insulin pump

Intervention Type DEVICE

Alterations in insulin pump therapy or carbohydrate consumption

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Insulin pump

Alterations in insulin pump therapy or carbohydrate consumption

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Type 1 diabetes ≥2 years.

* HbA1c;

* 58-63 mmol/mol (maximum 30% of participants) OR
* ≥ 64 mmol/mol (minimum 70% of participants)
* Insulin pump treatment ≥12 months
* CGM or isCGM use ≥6 months
* Novorapid use ≥4 weeks
* Carbohydrate counting and use of the insulin pump bolus calculator for most snacks and meals.
* Carbohydrate intake \>80 grams per day (assessed by review of intake recorded in the insulin pump during the 2 weeks prior to the screening visit)

Exclusion Criteria

* • Breast-feeding, pregnancy or planning to become pregnant.

* Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start.
* Use of hybrid closed-loop systems
* Daily use of paracetamol (acetaminophen)
* Alcohol or drug abuse.
* Severe cardiac disease or retinopathy contraindicating HbA1c \<53 mmol/mol.
* Other concomitant medical or psychological condition that according to the investigator's assessment makes the person unsuitable for study participation.
* Lack of compliance with key study procedures at the discretion of the investigator.
* Unacceptable adverse events at the discretion of the investigator

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No